108 related articles for article (PubMed ID: 2701744)
1. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders.
Macher JP; Sichel JP; Serre C; Von Frenckell R; Huck JC; Demarez JP
Neuropsychobiology; 1989; 22(2):77-82. PubMed ID: 2701744
[TBL] [Abstract][Full Text] [Related]
2. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
3. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.
Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G
Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
5. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
Guelfi JD; Ansseau M; Corruble E; Samuelian JC; Tonelli I; Tournoux A; Plétan Y
Int Clin Psychopharmacol; 1998 May; 13(3):121-8. PubMed ID: 9690979
[TBL] [Abstract][Full Text] [Related]
6. Controlled comparison of milnacipran and fluoxetine in major depression.
Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J
Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195
[TBL] [Abstract][Full Text] [Related]
7. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
[TBL] [Abstract][Full Text] [Related]
8. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
Arnold LM; Palmer RH; Gendreau RM; Chen W
Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
[TBL] [Abstract][Full Text] [Related]
9. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
[TBL] [Abstract][Full Text] [Related]
10. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
Steen A; Den Boer JA
Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
12. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA
Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
[TBL] [Abstract][Full Text] [Related]
13. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group.
Rouillon F; Warner B; Pezous N; Bisserbe JC
Int Clin Psychopharmacol; 2000 May; 15(3):133-40. PubMed ID: 10870871
[TBL] [Abstract][Full Text] [Related]
14. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.
Isaac MB; Isaac MT
Hum Psychopharmacol; 2003 Oct; 18(7):569-74. PubMed ID: 14533141
[TBL] [Abstract][Full Text] [Related]
15. Milnacipran. A review of its use in depression.
Spencer CM; Wilde MI
Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
[TBL] [Abstract][Full Text] [Related]
16. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life.
Rouillon F; Berdeaux G; Bisserbe JC; Warner B; Mesbah M; Smadja C; Chwalow J
J Affect Disord; 2000 Jun; 58(3):171-80. PubMed ID: 10802126
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression.
Van Amerongen AP; Ferrey G; Tournoux A
J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314
[TBL] [Abstract][Full Text] [Related]
18. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies.
von Frenckell R; Ansseau M; Serre C; Sutet P
Int Clin Psychopharmacol; 1990 Jan; 5(1):49-56. PubMed ID: 2185303
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of milnacipran in comparison with other antidepressants.
Bisserbe JC
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S43-50. PubMed ID: 12369610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
